Abstracts Archive - Page 1285 of 2607 - ACR Meeting Abstracts

Abstract Number: 1480 • 2018 ACR/ARHP Annual Meeting
Prognosis of Pneumonia in Rheumatoid Arthritis Patient: An Analysis of Using a Nationwide Administrative Database
Eishi Uechi^1,2 and Kiyohide Fushimi², ¹Division of Rheumatology, Tomishiro Central Hospital, Okinawa, Japan, ²Department of Health Policy and Informatics, Tokyo Medical and Dental University Graduate School, Tokyo, Japan
Background/Purpose: Pneumonia is the leading cause of mortality in RA patients. No research has been conducted on the prognosis of pneumonia in RA patients. This…
Abstract Number: 1481 • 2018 ACR/ARHP Annual Meeting
Are ACPA Associated with More Bone Loss over Time in Patients with RA?
Emma de Moel¹, Josephine Amkreutz¹, Lotte Heimans², Cornelia F. Allaart³, Tom W.J. Huizinga⁴ and Diane van der Woude⁴, ¹Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Internal Medicine, Leiden University Medical Center, Leiden, Netherlands, ³Department of Rheumatology, LUMC, Leiden, Netherlands, ⁴Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: Anti-citrullinated protein antibodies (ACPA) are one of the most important serological markers for rheumatoid arthritis (RA) and have been suggested to play a pathophysiologic…
Abstract Number: 1482 • 2018 ACR/ARHP Annual Meeting
Is 14.3.3η a Predictor of Development of Rheumatoid Arthritis in Patients with Early Undifferentiated Arthritis?
Karen Marie Carlsen¹, Nina Schmidt², Anne Duer³, Kim Hørslev-Petersen⁴, Cecilie Heegaard Brahe⁵, Merete Lund Hetland², Norma K Biln⁶, Michelle L Zaharik⁷, Bo Jannik Ejbjerg⁸, Lene Bak⁹, Michael Sejer Hansen¹⁰, Julia Sidenius Johansen¹¹, Hanne Merete Lindegaard¹², Jakob M. Møller¹³ and Mikkel Østergaard¹⁴, ¹Center for Rheumatology and Spine Diseases,, Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet Hillerød, Denmark, Hillerød, Denmark, ²Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup, Denmark, Glostrup, Denmark, ³Department of Radiology, Rigshospitalet Glostrup, Denmark, Glostrup, Denmark, ⁴King Christian the Xth Hospital for Rheumatic Diseases, Denmark, Graasten, Denmark, ⁵Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Rigshospitalet, Centre for Head and Orthopaedics, Rigshospitalet, Glostrup, Denmark, ⁶Augurex Life Sciences Corp, Vancouver, BC, Canada, ⁷Augurex Life Sciences Corp, Vancouver, DC, Canada, ⁸Rheumatology, Department of Rheumatology, Køge Hospital, Denmark, Køge, Denmark, ⁹Department of Radiology, Odense University Hospital, Denmark, Odense, Denmark, ¹⁰Reuma-Klinik Roskilde, Denmark, Roskilde, Denmark, ¹¹Dept. of Oncology, Department of Oncology, Copenhagen University Hospital, Herlev and Gentofte, Herlev, Denmark, ¹²Dept. of Rheumatology, Department of Rheumatology, Odense University Hospital, Denmark, Odense, Denmark, ¹³Department of Radiology, Copenhagen University Hospital Herlev, Copenhagen, Denmark, ¹⁴Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup, Denmark, Copenhagen, Denmark
Background/Purpose: Optimal management of rheumatoid arthritis (RA) requires early diagnosis and therefore sensitive methods for early identification of RA to prevent joint damage and disability.…
Abstract Number: 1483 • 2018 ACR/ARHP Annual Meeting
Comparison of Clinical Features of Seronegative and Seropositive Early Rheumatoid Arthritis: Blinded Data from the Ongoing Phase IIb Trial with the EP4 Receptor Antagonist CR6086 in DMARD-Naïve Patients
Giampaolo Giacovelli, Beatrice Barbetta, Cristina Vitalini, Nadia Brambilla, Massimo D'Amato, Federica Girolami and Lucio C. Rovati, Clinical Research Department, Rottapharm Biotech, Monza, Italy
Background/Purpose: Rheumatoid arthritis patients positive for rheumatoid factor (RF) or anti-cyclic citrullinated peptide antibody (ACPA) are considered to manifest an aggressive disease course compared with…
Abstract Number: 1484 • 2018 ACR/ARHP Annual Meeting
Value of Anti-RA33 Isotypes in an European Rheumatoid Arthritis Patient Cohort
Maresa Grundhuber¹, Daniela Sieghart², Günter Steiner², Maryam Poorafshar³ and Sascha Swiniarski¹, ¹Thermo Fisher Scientific, Freiburg, Germany, Freiburg, Germany, ²Division of Rheumatology, Department of Internal Medicine III, Medical University Vienna, Austria, Vienna, Austria, ³Thermo Fisher Scientific, Uppsala, Sweden, Uppsala, Sweden
Background/Purpose: Early diagnosis of rheumatoid arthritis (RA) leading to effective treatment is essential to improve prognosis and to prevent disease progression. Anti-cyclic citrullinated peptide (CCP)…
Abstract Number: 1485 • 2018 ACR/ARHP Annual Meeting
Survivin Measurements Improve Prediction of Rheumatoid Arthritis Among Patients with Unexplained Arthralgia
Malin C Erlandsson^1,2, Minna Turkkila³, Rille Pullerits^2,3,4 and Maria I Bokarewa^2,3, ¹Department of rheumatology and inflammation research, University of Gothenburg, Gothenburg, Sweden, ²Rheumatology Clinic, Sahlgrenska University Hospital, Gothenburg, Sweden, ³Department of Rheumatology, Institute of Medicine, Sahlgrenska Academy, Gothenburg University, Gothenburg, Sweden, ⁴Department of Clinical immunology and transfusion medicine, Sahlgrenska University Hospital, Gothenburg, Sweden
Background/Purpose: Early recognition of rheumatoid arthritis (RA) is believed to be the key to successful treatment of this disease. Symptoms of arthralgia often predate development…
Abstract Number: 1486 • 2018 ACR/ARHP Annual Meeting
Incidence of Subclinical Signs of Inflammation in Patients with New Onset of Non-Specific Musculoskeletal Symptoms and Anti-Citrullinated Peptide Positivity: First Interims Analysis of the Panora Trial
Michaela Koehm^1,2, Ulf Henkemeier^2,3, Tanja Rossmanith², Stephanie Dauth², Timm Oberwahrenbrock², Ann Christina Foldenauer², Karola Mergenthal⁴, Harald Burkhardt^2,3,5 and Frank Behrens^2,3,5, ¹Division of Rheumatology Goethe-University Frankfurt, Frankfurt/Main, Germany, ²Fraunhofer IME Branch for Translational Medicine and Pharmacology TMP, Frankfurt, Germany, ³Centre of Innovative Diagnostics and Therapeutics Rheumatology / Immunology at University Hospital Goethe-University Frankfurt, Frankfurt, Germany, ⁴Institute for General Practice Goethe-University, Frankfurt, Germany, ⁵Division of Rheumatology Goethe-University Frankfurt, Frankfurt, Germany
Background/Purpose: Rheumatoid Arthritis (RA) is a chronic inflammatory joint disease affecting approx. 1% of the adult population of Northern Europe and North America. Strategies for…
Abstract Number: 1487 • 2018 ACR/ARHP Annual Meeting
Correlation between Cytokine Levels and Power-Doppler Ultrasound Activity Is BMI Dependent, and Different in ACPA Positive and ACPA Negative RA with Wrist Arthritis
Ottar Gadeholt¹, Erin Arnold², Corinne Gorman³, Tobias Mueller⁴ and William Arnold², ¹Rheumatology/Immunology, Medical Clinic II, University Clinic Wuerzburg, Wuerzburg, Germany, ²Orthopedics and Rheumatology of the North Shore, Skokie, IL, ³Orthopaedics & Rheumatology of the North Shore, Skokie, IL, ⁴Department of Bioinformatics, University of Wuerzburg, Wuerzburg, Germany
Background/Purpose: Multiple cytokines are assumed to be involved in RA pathogenesis. It has been hypothesized that ACPA-negative RA with wrist affection constitutes a separate entity.…
Abstract Number: 1488 • 2018 ACR/ARHP Annual Meeting
Identification of Joint Locations That Are Poor Prognostic in an Early Seropositive Erosive RA Cohort
Patrick Durez¹, Sofie Robert², Alexandra Thiry³ and Harris A Ahmad³, ¹Cliniques Universitaires Saint-Luc, Institut de Recherche Expérimentale et Clinique (IREC), Brussels, Belgium, ²Bristol-Myers Squibb, Braine L’Alleud, Belgium, ³Bristol-Myers Squibb, Princeton, NJ
Background/Purpose: Patients (pts) with early RA often present with multiple and different areas of joint involvement. While the ACR and EULAR guidelines specify high disease…
Abstract Number: 1489 • 2018 ACR/ARHP Annual Meeting
“Continuous Reduction” in Serum RF Titers Predicts Low Disease Activity and Good Therapeutic Response in RA Patients Treated with TNF Inhibitors, but Does Not Relate to Clinical Outcomes during ABT Treatment
Takayoshi Owada¹, Kazuhiro Kurasawa¹, Yuta Takamura¹, Tomoyuki Miyao¹, Ayae Tanaka¹, Ryutaro Yamazaki², Satoko Arai¹, Reika Maezawa¹ and Masafumi Arima³, ¹Rheumatology, Dokkyo Medical University, Mibu, Tochigi, Japan, ²Rheumatology, Dokkyo Medical University, Mibu, tochigi, Japan, ³Rheumatology, Dokkyo Medical University, mibu-gun, Tochigi, Japan
Background/Purpose: Relative change of serum RF titer has been reported to correlate with those of RA disease activity. However, it is debatable whether serum RF…
Abstract Number: 1490 • 2018 ACR/ARHP Annual Meeting
Effects of Biologic Drugs on Prognosis of Rheumatoid Arthritis Among Patients with Poor Glycated Hemoglobic A1c (HbA1c) Control
Yusuke Miwa¹ and Tsuyoshi Kasama², ¹Division of Rheumatology, Department of Medicine, Showa University School of Medicine, Shinagawa-ku Tokyo, Japan, ²Div of Rheumatology, Showa University School of Med, Shinagawa-ku Tokyo, Japan
Background/Purpose: Poor control of glycated hemoglobic A1c (HbA1c) worsens prognosis for diabetes mellitus and various complicated diseases. Corticosteroids exacerbate poor HbA1c control. This study, investigated…
Abstract Number: 1491 • 2018 ACR/ARHP Annual Meeting
Oestrogen Levels and the Outcome of Leflunomide Treatment in Rheumatoid Arthritis
Alaa A A Mohamed¹, Manal Hassanien¹ and Esraa A Ahmed², ¹Rheumatology and Rehabilitation, Faculty of Medicine, Assiut University Hospitals, Assiut, Egypt, ²Pharmacology, Faculty of Medicine, Assiut University, Assiut, Egypt
Background/Purpose: Rheumatoid arthritis (RA) is an autoimmune and inflammatory polyarthritis involving mainly the synovial joints, and causing destruction of the articular cartilage and disabilities. Leflunomide…
Abstract Number: 1492 • 2018 ACR/ARHP Annual Meeting
Methotrexate Response in Early Rheumatoid Arthritis Predicted Using a Somamer Proteomic Assay
Carol Hitchon¹, Victor Spicer¹, Nathalie Carrier², Ang Gao¹, Hani El-Gabalawy¹, John Wilkins¹ and Gilles Boire³, ¹University of Manitoba, Winnipeg, MB, Canada, ²Centre intégré universitaire de santé et de services sociaux de l'Estrie -Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, QC, Canada, ³Rheumatology Division, Centre intégré universitaire de santé et de services sociaux de l'Estrie - Centre Hospitalier Universitaire de Sherbrooke and Universite de Sherbrooke, Sherbrooke, QC, Canada
Background/Purpose: Available clinical tools do not adequately identify treatment non-responders in early rheumatoid arthritis (RA) leading to delayed disease control. Tools informed by molecular phenotype…
Abstract Number: 1493 • 2018 ACR/ARHP Annual Meeting
Clinical Predictor Factors Associated with Sustained Disease Activity Among Patients with Early Rheumatoid Arthritis
Gabriela Gonzalez and Juan Molina, Rheumatology, La Paz University Hospital, Madrid, Spain
Background/Purpose: in rheumatoid arthritis (RA) patients the disease outcome has an unpredictable course and may differ even with an early diagnosis and treatment. Low disease…
Abstract Number: 1494 • 2018 ACR/ARHP Annual Meeting
Predictors of Persistence to Methotrexate Treatment in RA – Assessment of Different Modelling Approaches
Helga Westerlind¹, Mateusz Maciejewski², Thomas Frisell³, Scott Jelinsky⁴, Daniel Ziemek⁵ and Johan Askling¹, ¹Unit of Clinical Epidemiology, Department of Medicine, Solna, Karolinska Institutet, Stockholm, Sweden, ²Systems Immunology, Inflammation & Immunology,, Pfizer, Cambridge, MA, ³Clinical Epidemiology Unit, Department of Medicine, Solna, Karolinska Institutet, Stockholm, Sweden, ⁴Inflammation and Immunology, Pfizer Research and Development, Cambridge, MA, ⁵Systems Immunology, Inflammation & Immunology,, Pfizer, Berlin, Germany
Background/Purpose: As a step towards personalized medicine, we seek to identify patients with new-onset RA who are likely to remain well on MTX monotherapy. Patients…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].